SynthesisCurrent allergy and asthma reports2025
Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review.
Synthesis in Current allergy and asthma reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Burden of Respiratory Syncytial Virus Infection in Immunocompromised Adults: A Systematic Review of the Evidence From High-Income Countries.Infectious diseases and therapy · 2026Pooled it
- Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial.Frontiers in immunology · 2026Trial
- Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- Early bedside risk stratification using Charlson comorbidity index and NEWS2 in adults hospitalized with respiratory syncytial virus infection: a multicentre cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Adjuvanted RSVPreF3 vaccine impact over three respiratory syncytial virus seasons in older adults with comorbidities.ERJ open research · 2026Article
- Respiratory syncytial virus in adults aged ≥ 50 years in France: a database and time-series modelling analysis (2014-2020).Infection · 2026Observational
- Clinical and human burden of respiratory syncytial virus in older adults: a narrative review with emphasis on Italian data.Aging clinical and experimental research · 2026Review
- Burden of Respiratory Syncytial Virus in Older ADults in Nagasaki, Japan (Nagasaki ROAD): Preliminary Results (April 2024-March 2025) of a Prospective, Multicenter, Epidemiological Study.Infectious diseases and therapy · 2026Article
- Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017-2024.Infectious diseases and therapy · 2026Article
- Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities.Nature reviews. Drug discovery · 2026Review
- A Quarter-Century of Chronic Obstructive Pulmonary Disease in the Intensive Care Unit (2000-2025): A Bibliometric Roadmap of Thematic Evolution and Future Frontiers.International journal of chronic obstructive pulmonary disease · 2026Review
- Unlocking the value of RSV vaccination in Japan: a return on investment analysis using an integrated actuarial-macroeconomic model.Frontiers in public health · 2026Article
- Non-type 2 airway inflammation in severe asthma: from bench to bedside.Frontiers in immunology · 2026Review
- Expert Consensus Statement on the Disease Burden and Vaccination for Respiratory Syncytial Virus Infection in Adults.Tuberculosis and respiratory diseases · 2026Article
- Article
- Unraveling the dual immunomodulatory and immunogenic roles of the central conserved cysteine-rich region in respiratory syncytial virus G protein.Frontiers in microbiology · 2026Article
- The top 100 most cited articles on pediatric respiratory syncytial virus pneumonia over the last 30 years: a bibliometric analysis.Tropical medicine and health · 2025Article
- Addressing the Underestimated Burden of RSV in Older Adults in Europe: Epidemiology, Surveillance Gaps, and Public Health Implications.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAccumulating data indicate that asthma and chronic obstructive pulmonary disease (COPD) increase the risk of severe respiratory syncytial virus (RSV) infection. This systematic literature review assessed the burden of RSV disease among adults ≥ 18 years with asthma or COPD. RECENT
findingsData on the prevalence of asthma or COPD among RSV-infected adults, RSV-related hospitalizations, complications, and mortality were collected from studies published between January 1, 2000 and November 28, 2023 in PubMed, Embase, and grey literature. All extracted data were analyzed descriptively. Pooled estimates of asthma or COPD prevalence among RSV-infected adults were calculated from generalized linear mixed effects model meta-analyses. Forty studies were included. The prevalence of asthma and COPD among RSV-infected adults was high, especially in inpatient settings with pooled estimates (95% confidence interval) of 19.3% (15.0-24.6) for asthma and 30.8% (26.1-36.0) for COPD. Adults with asthma or COPD were more likely to be hospitalized following RSV infection than those without these conditions. The incidence rate ratios of hospitalization were 2.0-3.6 (crude) and 6.7-8.2 (adjusted) for asthma and 3.2-13.4 (crude) and 9.6-9.7 (adjusted) for COPD. The most frequently reported RSV-related complications were exacerbation of asthma (up to 64.9%) and COPD (up to ≥ 83.0%). In-hospital case fatality rates were 2.6-4.3% (asthma) and 2.8-17.8% (COPD). These comprehensive data showing a high RSV disease burden in adults with asthma or COPD can be used to inform policy decisions around RSV vaccines and improve preventive care in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.